Hospira – Recall of bleomycin injection

- On December 22, 2023, Hospira, a Pfizer company, announced a consumer level recall of one lot of bleomycin for injection, due to a confirmed customer report for the presence of glass particulate within a single vial.
-

Product Description	NDC#	Lot# (Expiration Date)
Bleomycin for injection, 15 units single-dose ONCO-TAIN™ glass fliptop vial	61703-332-18	BL12206A (6/30/2024)

- Bleomycin should be considered a palliative treatment useful in the management of neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents.
- Should a patient receive injectable product containing glass particulate matter as a result of this issue, the patient may experience adverse events including injection site reaction, localized vein inflammation or phlebitis, thrombus, embolus and/or end-organ granuloma or life-threatening blood clot events. The risk is reduced by the possibility of detection, as the label contains a statement directing the healthcare professional to visually inspect the product for particulate matter and discoloration prior to administration.
- To date, Hospira has not received any reports of adverse events related to this recall.
- Anyone with the affected lots on hand should stop distribution and return product.
- Contact Pfizer/Hospira at 1-800-438-1985 or access **www.pfizermedinfo.com** for questions regarding this recall.